Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy: Withdrawals due to adverse events
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes withdrawal due to adverse event ( compared with other anti‐emetic monotherapy (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy Withdrawal due to adverse event ( · people with chemotherapy‐induced nausea and vomiting It is very uncertain whether cannabinoid plus other anti‐emetic agent changes withdrawal due to adverse event ( compared with other anti‐emetic monotherapy (very low certainty). Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane Headline outcomes only | RR 7 [0.88, 55] | 2 studies · 105 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.